MedPath

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Conditions
Metastatic Renal Cell Cancer
Registration Number
NCT00655252
Lead Sponsor
Novartis Pharmaceuticals
Brief Summary

This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.

Detailed Description

Not available

Recruitment & Eligibility

Status
NO_LONGER_AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (40)

The Cancer Institute, St. Joseph Medical Center

πŸ‡ΊπŸ‡Έ

Towson, Maryland, United States

Indiana University Cancer center

πŸ‡ΊπŸ‡Έ

Indianapolis, Indiana, United States

Cliveland Clinic Foundation

πŸ‡ΊπŸ‡Έ

Cleveland, Ohio, United States

Lakeridhe Health Corp - Oshawa

πŸ‡¨πŸ‡¦

Oshawa, Ontario, Canada

Missouri Cancer Associates

πŸ‡ΊπŸ‡Έ

Columbia, Missouri, United States

Moncton Hospital

πŸ‡¨πŸ‡¦

Moncton, New Brunswick, Canada

University of Colorado Health Sciences Center/Anschutz Pavillion

πŸ‡ΊπŸ‡Έ

Aurora, Colorado, United States

Saskatoon Cancer Center

πŸ‡¨πŸ‡¦

Saskatoon, Saskatchewan, Canada

Royal Victoria Hospital

πŸ‡¨πŸ‡¦

Barrie, Ontario, Canada

QE ll Health Sciences Centre

πŸ‡¨πŸ‡¦

Halifax, Nova Scotia, Canada

Centre Hospitalier Universitaire de Sherbrooke

πŸ‡¨πŸ‡¦

Sherbrooke, Quebec, Canada

Washington University/Siteman Cancer Center

πŸ‡ΊπŸ‡Έ

St. Louis, Missouri, United States

St Luke's Wing, Royal Surrey County Hospital

πŸ‡¬πŸ‡§

Surrey, United Kingdom

Highlands oncology Group, PA

πŸ‡ΊπŸ‡Έ

Springdale, Arkansas, United States

MD Anderson Cancer Center - Orlando

πŸ‡ΊπŸ‡Έ

Orlando, Florida, United States

Cancer Centers of Florida, P.A.

πŸ‡ΊπŸ‡Έ

Ocoee, Florida, United States

Heartland Hematology-Oncology Associates, Inc.

πŸ‡ΊπŸ‡Έ

Kansas City, Missouri, United States

Blumenthal Cancer Center/Carolinas Medical Center

πŸ‡ΊπŸ‡Έ

Charlotte, North Carolina, United States

Gabrail Cancer Center

πŸ‡ΊπŸ‡Έ

Canton, Ohio, United States

Cleo Craig Memorial Cancer & Research Clinic

πŸ‡ΊπŸ‡Έ

Lawton, Oklahoma, United States

Cancer centers of the Carolinas

πŸ‡ΊπŸ‡Έ

Greenville, South Carolina, United States

Novartis Investigative Site

πŸ‡ΉπŸ‡·

Izmir, Turkey

Sault Area Hospital - General Site

πŸ‡¨πŸ‡¦

Sault Ste Marie, Ontario, Canada

Les Urologues Associes du CHUM

πŸ‡¨πŸ‡¦

Montreal, Quebec, Canada

Novartis Investigative site

πŸ‡©πŸ‡ͺ

Munster, Germany

Royal Bournemouth Hospital

πŸ‡¬πŸ‡§

Bournemouth, United Kingdom

Novartis Investidative Site

πŸ‡©πŸ‡ͺ

Nurnberg, Germany

Addenbrookes Hospital

πŸ‡¬πŸ‡§

Cambridge, United Kingdom

British Haematology and Oncology Centre

πŸ‡¬πŸ‡§

Bristol, United Kingdom

CRUK

πŸ‡¬πŸ‡§

Glasgow, United Kingdom

Southampton University Hospital NHS Trust,

πŸ‡¬πŸ‡§

Hampshire, United Kingdom

Royal Free Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Oncology & Haematology Clinical Tirals Unit

πŸ‡¬πŸ‡§

Leicester, United Kingdom

Guy's and St. Thomas' NHS Foundation Trust

πŸ‡¬πŸ‡§

London, United Kingdom

Royal Marsden Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

The Christie Hospital

πŸ‡¬πŸ‡§

Manchester, United Kingdom

Newcastle General Hospital

πŸ‡¬πŸ‡§

Newcastle, United Kingdom

Mount Vernon Cancer Centre

πŸ‡¬πŸ‡§

Northwood, United Kingdom

Singleton Hospital

πŸ‡¬πŸ‡§

Swansea, United Kingdom

Henry Ford Health System

πŸ‡ΊπŸ‡Έ

Detroit, Michigan, United States

Β© Copyright 2025. All Rights Reserved by MedPath